Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orebatinib Phase II study in CML resistant or intolerant to first/second-generation TKIs
ChiCTR2400092646Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olverembatinib in chronic myelogenous leukemia (CML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Major molecular response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2400092646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092646.